Antimicrobial activity and spectrum investigation of eight broad- spectrum β-lactam drugs: A 1997 surveillance trial in 102 medical centers in the United States

Diagnostic Microbiology and Infectious Disease

Volumn 30, Issue 3, 1998, Pages 215-228

  Jones, Ronald N ^a   Pfaller, Michael A ^b   Doern, Gary V ^b   Erwin, Meridith E ^b   Hollis, Richard J ^b  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER; ESCHERICHIA COLI; GOOD LABORATORY PRACTICE; GRAM NEGATIVE INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE AEROBIC RODS AND COCCI; GRAM-NEGATIVE ANAEROBIC BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS; HUMANS;

EID: 0032031826     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00234-4     Document Type: Article

References (48)

1. Barradell LB, Bryson HM. Cefepime a review of its antibacterial activity, pharmacokinetic properties and therapeutic use . Drugs. 47:1994;471-505.
2. Berne TV, Yellin AE, Appelbaum MD, Heseltine PN, Gill MA. A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surg Gynecol Obstet. 177:(suppl):1993;18-22.
3. Bolmstrom A, Arvidson S, Ericson M, Karlsson A. A novel technique for direct quantification of antimicrobial susceptibility of microorganisms (Abstract 1209). 1988;ICAAC, Los Angeles.
4. Brown DFJ, Brown L. Evaluation of the Etest a novel method of quantifying antimicrobial activity . J Antimicrob. 27:1991;185-190.
5. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial Gram-negative bacilli in the United States. J Infect Dis. 170:1994;1622-1625.
6. Bush K. Is it important to identify extended-spectrum beta-lactamase-producing isolates? Eur J Clin Microbiol Infect Dis. 15:1996;361-364.
7. Fournier B, Lagrange PH, Philippon A. In vitro susceptibility of Klebsiella oxytoca strains to 13 β-lactams in the presence and absence of β-lactamase inhibitors. J Antimicrob Chemother. 37:1996;931-942.
8. OXY-2. Antimicrob Agents Chemother. 40:1996;454-459.
9. Frei R, Jones RN, Pignatari AC, Yamane N, Marco F, Hoban DJ. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime. Diagn Microbiol Infect Dis. 18:1994;167-173.
10. Fuchs PC, Jones RN, Barry AL, Ayers LW, Gavan TL, Gerlach EH. In vitro activity of carumonam (Ro 17-2301), BMY 28142, aztreonam, ceftazidime against 7,260 consecutive clinical bacterial isolates. Diagn Microbiol Infect Dis. 5:1986;345-349.
11. Fung-Tomc J, Dougherty T, DeOrio F, Simich-Jacobson V, Kessler RE. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to β-lactamase levels. Antimicrob Agents Chemother. 33:1989;489-502.
12. Fung-Tomc JC, Gradelski E, Huczko E, Doughterty TJ, Kessler RE, Bonner DP. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother. 40:1996;1289-1293.
13. Gouin F, Papazian L, Martin C, Albanese J, Dubec A, Domaet Y, Veyssier P, Leroy J, Gres JJ, Rollin C. A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care. J Antimicrob Chemother. 32:(suppl B):1993;205-214.
14. Gradelski E, Fung-Tomc J, Huczko E, Kessler RE. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother. 32:(suppl B):1993;75-80.
15. Hoepelman AIM, Kieft H, Aoun M. International comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother. 32:(suppl B):1993;175-186.
16. Jacoby GA, Carreras I. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother. 34:1990;858-862.
17. Jacoby GA, Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 34:1996;908-911.
18. Jaurequi L, Matzke D, Scott M, Minns P, Hageage G. Cefepime as treatment for osteomyelitis and other bacterial infections. J Antimicrob Chemother. 32:(suppl B):1993;141-149.
19. Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med. 100:(suppl 6A):1996;3S-12S.
20. Jones RN, Barrett MS, Erwin ME. In vitro activity of FK-037, a new parenteral cephalosporin. J Antimicrob Chemother. 33:1994;137-144.
21. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group 1 β-lactamase-producing strains resistant to ceftazidime. Diagn Microbiol Infect Dis. 19:1994;33-38.
22. Kessler RE, Bies M, Buch RE, Chisholm DR, Puisiano TA, Tsai YA, Misiek M, Price KE, Leitner F. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum β-lactam antibiotics. Antimicrob Agents Chemother. 27:1985;207-216.
23. Kessler RE, Fung-Tomc J. Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period. Am J Med. 100:(suppl 6A):1996;13S-19S.
24. Lemozy J, Sirot D, Chanal C, Huc C, Labia R, Debernat H, Sirot J. First characterization of inhibitor-resistant TEM (IRT) β-lactamases in Klebsiella pneumoniae strains. Antimicrob Agents Chemother. 33:1995;2580-2582.
25. McCabe R, Chirurgi V, Farkas SA, Haddow A, Heinz G, Greene S. A new therapeutic option for the treatment of pneumonia. Am J Med. 100:(suppl 6A):1996;60S-67S.
26. Naito T, Aburaki S, Kamachi H, Narita Y, Okumura J, Kawaguchi H. Synthesis and structure-active relationships of a new series of cephalosporins. BMY 28142 and related compounds. J Antibiot. 39:1986;1092-1107.
27. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
28. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
29. Neu HC. Safety of cefepime A new extended-spectrum parenteral cephalosporin . Am J Med. 100:(suppl 6A):1996;68S-75S.
30. Newton ER, Yeomans ER, Pastorek JG, Soper DE, Hemsell DL. Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynecological infections. J Antimicrob Chemother. 32:(suppl B):1993;195-204.
31. Palzkill T, Thomson KS, Sanders CC, Moland ES, Huang W, Milligan TW. New variant of TEM-10 β-lactamase gene produced by a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother. 39:1995;1199-1200.
32. Papsian CJ, Kinney J, Coffman S, Hollis RJ, Pfaller MA. Transmission of Citrobacter koseri from mother to infant documented by ribotyping and pulsed-field gel electrophoresis. Diagn Microbiol Infect Dis. 26:1996;63-67.
33. Pechere JC, Vladoianu IR. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother. 29:1992;563-573.
34. Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis JR, Edmond MB, Wenzel RP. Inducible Amp C β-lactamase producing Gram-negative bacilli from blood stream infections frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE) . Diagn Microbiol Infect Dis. 28:1997;211-219.
35. Pfaller MA, Wendt C, Hollis RJ, Wenzel RP, Fritscel SJ, Neubauer JJ, Herwaldt LA. Comparative evaluation of an automated ribotyping system versus pulsed-field gel electrophoresis for epidemiological typing of clinical isolates of Escherichia coli and Pseudomonas aeruginosa from patients with recurrent Gram-negative bacteremia. Diagn Microbiol Infect Dis. 25:1996;1-8.
36. Phelps DJ, Carlton DD, Farrell CA, Kessler RE. Affinity of cephalosporins for β-lactamases as a factor in antibacterial efficacy. Antimicrob Agents Chemother. 29:1986;845-848.
37. Philippon A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 13:1994;17-29.
38. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med. 100:(suppl 6A):1996;83S-89S.
39. Saez-Llorens X, Castano E, Garcia R, Baez C, Perez M, Tejeira F, McCracken GH Jr. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother. 39:1995;937-940.
40. Sanders WE, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis. 23:1996;454-461.
41. Schrank JH Jr, Kelley JW, McAllister CK. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. Clin Infect Dis. 20:1995;56-58.
42. Schwartz R, Das Young LR, Ramirez-Ronda C, Frank E. Current and future management of serious skin and skin-structure infections. Am J Med. 100:(suppl 6A):1996;90S-95S.
43. IMP) in gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol. 34:1996;2909-2913.
44. Sharifi R, Geckler R, Childs S. Treatment of urinary tract infections Selecting an appropriate broad-spectrum antibiotic for nosocomial infections . Am J Med. 100:(suppl 6A):1996;76S-82S.
45. Tauber MG, Hackbarth CJ, Scott KG, Rusnak MG, Sande MA. New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother. 27:1995;340-342.
46. Thauvin-Eliopoulos C, Tripodi MF, Moellering RC Jr, Eliopoulos GM. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents and Chemother. 41:1997;1053-1057.
47. Thornsberry C, Yee YC. Comparative activity of eight antibiotics against clinical bacterial isolates from the United States Broth microdilution (MicroScan) and the Etest method . Am J Med. 100:(suppl 6A):1996;26S-38S.
48. Washington JA, Jones RN, Gerlach EH, Murray PR, Allen SC, Knapp CC. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftaizidime, and cefuroxime. Antimicrob Agents Chemother. 37:1993;1696-1700.